Literature DB >> 22021173

The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease.

Susan H Fox1, Regina Katzenschlager, Shen-Yang Lim, Bernard Ravina, Klaus Seppi, Miguel Coelho, Werner Poewe, Olivier Rascol, Christopher G Goetz, Cristina Sampaio.   

Abstract

The objective was to update previous evidence-based medicine reviews of treatments for motor symptoms of Parkinson's disease published between 2002 and 2005. Level I (randomized, controlled trial) reports of pharmacological, surgical, and nonpharmacological interventions for the motor symptoms of Parkinson's disease between January 2004 (2001 for nonpharmacological) and December 2010 were reviewed. Criteria for inclusion, clinical indications, ranking, efficacy conclusions, safety, and implications for clinical practice followed the original program outline and adhered to evidence-based medicine methodology. Sixty-eight new studies qualified for review. Piribedil, pramipexole, pramipexole extended release, ropinirole, rotigotine, cabergoline, and pergolide were all efficacious as symptomatic monotherapy; ropinirole prolonged release was likely efficacious. All were efficacious as a symptomatic adjunct except pramipexole extended release, for which there is insufficient evidence. For prevention/delay of motor fluctuations, pramipexole and cabergoline were efficacious, and for prevention/delay of dyskinesia, pramipexole, ropinirole, ropinirole prolonged release, and cabergoline were all efficacious, whereas pergolide was likely efficacious. Duodenal infusion of levodopa was likely efficacious in the treatment of motor complications, but the practice implication is investigational. Entacapone was nonefficacious as a symptomatic adjunct to levodopa in nonfluctuating patients and nonefficacious in the prevention/delay of motor complications. Rasagiline conclusions were revised to efficacious as a symptomatic adjunct, and as treatment for motor fluctuations. Clozapine was efficacious in dyskinesia, but because of safety issues, the practice implication is possibly useful. Bilateral subthalamic nucleus deep brain stimulation, bilateral globus pallidus stimulation, and unilateral pallidotomy were updated to efficacious for motor complications. Physical therapy was revised to likely efficacious as symptomatic adjunct therapy. This evidence-based medicine review updates the field and highlights gaps for research.
Copyright © 2011 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22021173     DOI: 10.1002/mds.23829

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  148 in total

1.  Cholinergic manipulation of motor disability and L-DOPA-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated common marmosets.

Authors:  M J Jackson; T Swart; R K B Pearce; P Jenner
Journal:  J Neural Transm (Vienna)       Date:  2014-02       Impact factor: 3.575

Review 2.  Pathogenesis-targeted, disease-modifying therapies in Parkinson disease.

Authors:  Amaal AlDakheel; Lorraine V Kalia; Anthony E Lang
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

3.  Assessment of Duodopa® effects on quality of life of patients with advanced Parkinson's disease and their caregivers.

Authors:  Rosella Ciurleo; Francesco Corallo; Lilla Bonanno; Viviana Lo Buono; Giuseppe Di Lorenzo; Roberta Versaci; Cettina Allone; Rosanna Palmeri; Placido Bramanti; Silvia Marino
Journal:  J Neurol       Date:  2018-06-27       Impact factor: 4.849

4.  Neurodegenerative disease: Multiple system atrophy-new insight from prospective studies.

Authors:  Werner Poewe; Florian Krismer
Journal:  Nat Rev Neurol       Date:  2015-07-21       Impact factor: 42.937

Review 5.  Banisteriopsis caapi, a Forgotten Potential Therapy for Parkinson's Disease?

Authors:  Atbin Djamshidian; Sabine Bernschneider-Reif; Werner Poewe; Andrew J Lees
Journal:  Mov Disord Clin Pract       Date:  2015-10-06

Review 6.  Motor Complications of Dopaminergic Medications in Parkinson's Disease.

Authors:  Maria Eliza Freitas; Christopher W Hess; Susan H Fox
Journal:  Semin Neurol       Date:  2017-05-16       Impact factor: 3.420

Review 7.  Continuous drug delivery in Parkinson's disease.

Authors:  Marina Senek; Dag Nyholm
Journal:  CNS Drugs       Date:  2014-01       Impact factor: 5.749

Review 8.  Parkinsonian syndromes.

Authors:  David R Williams; Irene Litvan
Journal:  Continuum (Minneap Minn)       Date:  2013-10

9.  Is there room for new non-dopaminergic treatments in Parkinson's disease?

Authors:  Manuela Pilleri; Konstantinos Koutsikos; Angelo Antonini
Journal:  J Neural Transm (Vienna)       Date:  2012-12-11       Impact factor: 3.575

10.  Effects of the 5HT2C antagonist SB242084 on the pramipexole-induced potentiation of water contrafreeloading, a putative animal model of compulsive behavior.

Authors:  Chiara Schepisi; Lorenza De Carolis; Paolo Nencini
Journal:  Psychopharmacology (Berl)       Date:  2012-12-16       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.